Additionally, GLI1 upregulation has also been recently reported to correlate with treatment resistance in RMS and Ewing’s sarcoma (ES), thereby suggesting that GLI1 targeting may benefit patients with RMS and ES by reducing multidrug resistance [73]. This evidence concerns the gene GLI1 and Ewing sarcoma.